These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Knowledge and future preference of Chinese women in a major public hospital in Hong Kong after undergoing non-invasive prenatal testing for positive aneuploidy screening: a questionnaire survey. Kou KO; Poon CF; Tse WC; Mak SL; Leung KY BMC Pregnancy Childbirth; 2015 Sep; 15():199. PubMed ID: 26330276 [TBL] [Abstract][Full Text] [Related]
3. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
4. Facilitating autonomous, confident and satisfying choices: a mixed-method study of women's choice-making in prenatal screening for common aneuploidies. Chen A; Tenhunen H; Torkki P; Peltokorpi A; Heinonen S; Lillrank P; Stefanovic V BMC Pregnancy Childbirth; 2018 May; 18(1):119. PubMed ID: 29720125 [TBL] [Abstract][Full Text] [Related]
5. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies. Audibert F; Gagnon A; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753 [TBL] [Abstract][Full Text] [Related]
6. Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age. Allyse M; Sayres LC; Goodspeed TA; Cho MK J Perinatol; 2014 Jun; 34(6):429-34. PubMed ID: 24603453 [TBL] [Abstract][Full Text] [Related]
7. Canadian women's attitudes toward noninvasive prenatal testing of fetal DNA in maternal plasma (.). Pariente G; Hasan L; Gadot Y; De Souza LR; Lebovic G; Berger H J Matern Fetal Neonatal Med; 2016 Dec; 29(24):4008-14. PubMed ID: 26940147 [TBL] [Abstract][Full Text] [Related]
8. Prenatal screening for Down syndrome: popularity, perceptions and factors associated with acceptance or refusal of testing. Pop-Tudose ME; Armean P; Pop IV J Matern Fetal Neonatal Med; 2022 Dec; 35(25):6505-6509. PubMed ID: 33910457 [TBL] [Abstract][Full Text] [Related]
9. Nuchal translucency measurement in the era of prenatal screening for aneuploidy using cell free (cf)DNA. O'Brien BM; Halliday J; Lambert-Messerlian G; Eklund EE; Kloza E; Palomaki GE Prenat Diagn; 2017 Mar; 37(3):303-305. PubMed ID: 28124379 [No Abstract] [Full Text] [Related]
10. Decision-making for prenatal genetic screening: how will pregnant women navigate a growing number of aneuploidy and carrier screening options? Farrell RM; Pierce M; Collart C; Yao M; Coleridge M; Chien EK; Rose SS; Lintel M; Perni U; Edmonds BT BMC Pregnancy Childbirth; 2021 Dec; 21(1):806. PubMed ID: 34863134 [TBL] [Abstract][Full Text] [Related]
11. Prenatal screening: current practice, new developments, ethical challenges. de Jong A; Maya I; van Lith JM Bioethics; 2015 Jan; 29(1):1-8. PubMed ID: 25521968 [TBL] [Abstract][Full Text] [Related]
12. Determinants associated with making prenatal screening decisions in a national study. Bakst S; Romano-Zelekha O; Ostrovsky J; Shohat T J Obstet Gynaecol; 2019 Jan; 39(1):41-48. PubMed ID: 30244627 [TBL] [Abstract][Full Text] [Related]
13. State-wide utilization and performance of traditional and cell-free DNA-based prenatal testing pathways: the Victorian Perinatal Record Linkage (PeRL) study. Lindquist A; Hui L; Poulton A; Kluckow E; Hutchinson B; Pertile MD; Bonacquisto L; Gugasyan L; Kulkarni A; Harraway J; Howden A; McCoy R; Da Silva Costa F; Menezes M; Palma-Dias R; Nisbet D; Martin N; Bethune M; Poulakis Z; Halliday J Ultrasound Obstet Gynecol; 2020 Aug; 56(2):215-224. PubMed ID: 31625225 [TBL] [Abstract][Full Text] [Related]
14. Ethical considerations for choosing between possible models for using NIPD for aneuploidy detection. Deans Z; Newson AJ J Med Ethics; 2012 Oct; 38(10):614-8. PubMed ID: 22745108 [TBL] [Abstract][Full Text] [Related]
15. Use of a DNA method, QF-PCR, in the prenatal diagnosis of fetal aneuploidies. Langlois S; Duncan A; ; J Obstet Gynaecol Can; 2011 Sep; 33(9):955-960. PubMed ID: 21923994 [TBL] [Abstract][Full Text] [Related]
16. Routinization of prenatal screening with the non-invasive prenatal test: pregnant women's perspectives. van der Meij KRM; Njio A; Martin L; Gitsels-van der Wal JT; Bekker MN; van Vliet-Lachotzki EH; van der Ven AJEM; Kater-Kuipers A; Timmermans DRM; Sistermans EA; Galjaard RH; Henneman L; Eur J Hum Genet; 2022 Jun; 30(6):661-668. PubMed ID: 34385671 [TBL] [Abstract][Full Text] [Related]
17. Considering medical risk information and communicating values: A mixed-method study of women's choice in prenatal testing. Chen A; Tenhunen H; Torkki P; Heinonen S; Lillrank P; Stefanovic V PLoS One; 2017; 12(3):e0173669. PubMed ID: 28355226 [TBL] [Abstract][Full Text] [Related]
18. Pregnant couples at increased risk for common aneuploidies choose maximal information from invasive genetic testing. van der Steen SL; Diderich KE; Riedijk SR; Verhagen-Visser J; Govaerts LC; Joosten M; Knapen MF; Van Opstal D; Srebniak MI; Tibben A; Galjaard RJ Clin Genet; 2015 Jul; 88(1):25-31. PubMed ID: 25134982 [TBL] [Abstract][Full Text] [Related]
19. Limits to the scope of non-invasive prenatal testing (NIPT): an analysis of the international ethical framework for prenatal screening and an interview study with Dutch professionals. Kater-Kuipers A; Bunnik EM; de Beaufort ID; Galjaard RJH BMC Pregnancy Childbirth; 2018 Oct; 18(1):409. PubMed ID: 30340550 [TBL] [Abstract][Full Text] [Related]
20. Prenatal cell-free DNA screening for fetal aneuploidy in pregnant women at average or high risk: Results from a large US clinical laboratory. Guy C; Haji-Sheikhi F; Rowland CM; Anderson B; Owen R; Lacbawan FL; Alagia DP Mol Genet Genomic Med; 2019 Mar; 7(3):e545. PubMed ID: 30706702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]